Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: Implications for ileal transposition

Surgery for Obesity and Related Diseases

Volumn 10, Issue 5, 2014, Pages 780-786

  Buchwald, Henry ^a   Dorman, Robert B ^a   Rasmus, Nikolaus F ^a   Michalek, Van N ^a   Landvik, Nichol M ^a   Ikramuddin, Sayeed ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Duodenal switch; GLP 1; Leptin; PYY

Indexed keywords

FOOD HYDROLYSATE; GLUCAGON LIKE PEPTIDE 1; LEPTIN; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; PEPTIDE YY; UNCLASSIFIED DRUG; ELECTROLYTE; PROTEIN HYDROLYSATE;

ARTICLE; BILIOPANCREATIC BYPASS; CECUM; HUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STIMULATION; TERMINAL ILEUM; ANALYSIS OF VARIANCE; BLOOD; FOOD; ILEUM; METABOLISM; OBESITY, MORBID; SECRETION (PROCESS); TRANSPLANTATION;

ANALYSIS OF VARIANCE; CECUM; ELECTROLYTES; FOOD; GLUCAGON-LIKE PEPTIDE 1; HUMANS; ILEUM; LEPTIN; OBESITY, MORBID; PEPTIDE YY; PHYSICAL STIMULATION; PROTEIN HYDROLYSATES;

EID: 84928829767     PISSN: 15507289     EISSN: 18787533     Source Type: Journal    
DOI: 10.1016/j.soard.2014.01.032     Document Type: Article

References (52)

1. Buchwald H, Buchwald JN. Evolution of operative procedures for the management of morbid obesity 1950-2000. Obes Surg 2002; 12: 705-17.
2. Buchwald H, Varco RL, editors. Metabolic surgery. New York: Grune and Stratton; 1978.
3. Pories WJ, Swanson MS, MacDonald K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222:339-52.
4. Scopinaro N, Adami GF, Marinari GMFS, et al. Biliopancreatic diversion. World J Surg 1998; 22:936-46.
5. Klein S, Fabbrini E, Patterson B.W., et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity 2012; 20:1266-72.
6. Cohen R, Caravatto PP, Correa J.L., et al. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis 2012; 8:375-80.
7. Gagner M. Surgical treatment of nonseverely obese patients with type 2 diabetes mellitus: sleeve gastrectomy with ileal transposition (SGIT) is the same as the neuroendocrine brake (NEB) procedure or ileal interposition associated with sleeve gastrectomy (II-SG), but ileal interposition with diverted sleeve gastrectomy (II-DSG) is the same as duodenal switch. Surg Endosc 2001; 25:655-6.
8. DePaula AL, Stival AR, DePaula C.C., Halpern A., Vencio S. Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases. J Gastrointest Surg 2012; 16:967-76.
9. Hernandez EJ, Whitcomb DC, Vigna S.R., Taylor IL. Saturable binding of circulating peptide YY in the dorsal vagal complex of rats. Am J Physiol Gastrointest Liver Physiol 1994; 226:G511-6.
10. Druce MR, Small CJ, Bloom SR. Minireview: gut peptides regulating satiety. Endocrinology 2004; 145:2660-5.
11. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003; 349:926-8.
12. Savage AP, Adrian TE, Carolan G, Chatterjee V.K., Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28:166-70.
13. Spiller RC, Trotman IF, Adrian T.E., et al. Further characterization of the 'ileal brake' reflex in man-effect of ileal infusion of partial digests of fat, protein, and starch on jejunal mortality and release of neurotensin, enteroglucagon, and peptide YY. Gut 1988; 29:1042-51.
14. Spiller RC, Trotman IF, Higgins B.E., et al. The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984; 25: 365-74.
15. Ballantyne GH. Peptide YY(1-36) and peptide (YY(3-36): Part I. Distribution, release and actions. Obes Surg 2006; 16:651-8.
16. Sileno AP, Brandt GC, Spann B.M., Quay SC. Lower mean weight after 14 days intravenous administration peptide YY(3-36) (PYY(3-36)) in rabbits. Int J Obes 2006; 30:68-72.
17. Batterham RL, Cowley MA, Small C.J., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-4.
18. Batterham RL, Cohen MA, Ellis S.M., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-8.
19. Neary NM, Small CJ, Druce M.R., et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146:5120-7.
20. Adrian TE, Savage AP, Sagor G.R., et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89:484-9.
21. Lluis F, Gomez G, Fujimura M., Greeley GH Jr, Thompson JC. Peptide YY inhibits nutrient-, hormonal-, and vagally-stimulated pancreatic exocrine secretion. Pancreas 1987; 2:454-62.
22. Hosotani R, Inoue K, Kogire M., et al. Effect of natural peptide YY on pancreatic secretion and cholecystokinin release in conscious dogs. Dig Dis Sci 1989; 34:468-73.
23. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009; 587:27-32.
24. Lius F, Salva JA, Thompson JC. Peptide YY inhibits the insulino-tropic action of gastric inhibitory polypeptide. Gastroenterology 1989; 96:690-4.
25. Guo YS, Singh P, DeBouno J.F., Thompson JC. Effect of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs. Pancreas 1988; 3:128-34.
26. Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell. The view from within. Diabetes 2006; 55:S70-7.
27. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
28. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretin of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86:3717-23.
29. Mannucci E, Ognibene A, Cremasco F., et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 2000; 17:713-9.
30. Nauck M, Stockmann F, Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29:46-52.
31. Adrian TE, Ferre G-L, Bacarese-Hamilton AJ, Fuessl H.S., Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89:1070-7.
32. Greeley GH Jr, Hashimoto T, Izukura M., et al. A comparison of intraduodenally and intracolonically administered nutrients on the release of peptide-YY in the dog. Endocrinology 1989; 125: 1761-5.
33. Zhang T, Brubaker PL, Thompson J.C., Greeley GH Jr. Characterization of peptide-YY release in response to intracolonic infusion of amino acids. Endocrinology 1993; 132:553-7.
34. Aponte GW, Fink AS, Meyer J.H., Tatemoto K., Taylor IL. Regional distribution and release of peptide YY with fatty acids of different chain length. Am J Physiol 1985; 249:G745-50.
35. Adrian TE, Ballantyne GH, Longo W.E., et al. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 1993; 34:1219-24.
36. Onaga T, Zabielski R, Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides 2002; 23:279-90.
37. Zhang T, Uchida T, Gomez G., Lluis F, Thompson JC, Greeley GH Jr. Neural regulation of peptide YY secretion. Regulatory Peptides 1993; 48:321-8.
38. Rudnicki M, Rigel DF, McFadden DW. Vagal cooling blocks circulating neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) release. J Surg Res 1991; 51:40-5.
39. Ballantyne GH, Goldenring JR, Savoca P.E., et al. Cyclic AMP-mediated release of peptide YY (PYY) from the isolated perfused rabbit distal colon. Regulatory Peptides 1993; 47:117-26.
40. Greeley GH Jr, Jeng YJ, Gomez G, et al. Evidence for regulation of peptide-YY release by the proximal gut. Endocrinology 1989; 124: 1438-43.
41. Naslund E, Bogefors J, Skogar S., et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 1999; 277:R910-6.
42. Ali-Rachedi A, Varndell IM, Adrian T.E., et al. Peptide YY (PYY) immunoreactivity is co-stored with glucagon related immunoreactants in endocrine cells of the gut and pancreas. Histochem 1984; 80: 487-91.
43. Bottcher G, Sjolund K, Ekblad E., Hakanson R, Schwartz TW, Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regulatory Peptides 1984; 8:261-6.
44. Bottcher G, Alumets J, Hakanson R., Sundler F. Coexistence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regulatory Peptides 1986; 13:283-91.
45. Nilsson O, Bilchik AJ, Goldenring J.R., Ballantyne GH, Adrian TE, Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 1991; 129:139-48.
46. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003; 52:252-9.
47. Jimenez A, Casamitjana R, Viaplana-Masclans J, Lacy A., Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 2013; 36: 2062-9.
48. Shah M, Law JH, Micheletto F, et al. The contribution of endogenous glucagon-like peptide-1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes, published ahead of print October 2, 2013.
49. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133:233-40.
50. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140:1687-94.
51. Rask E, Olsson T, Soderberg S., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24:1640-5.
52. Pilichiewicz AN, Little TJ, Brennan I.M., et al. Effects of load and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. Am J Physiol 2006; 290:R668-77.